Amgen (NSDQ:AMGN) announced today that it successfully completed its $1.9 billion acquisition of Five Prime Therapeutics (NSDQ:FPRX). Thousand Oaks, Calif.-based Amgen has officially acquired South San Francisco-based Five Prime for $38 per share in cash, reaching an equity value of approximately $1.9 billion. The acquisition was initially announced on March 4, 2021. As of the […]
Mergers & Acquisitions
Better Therapeutics to go public via $113M merger with SPAC
Better Therapeutics announced today that, through a $113 million merger with Mountain Crest Acquisition Corp II, it will go public. Mountain Crest, a publicly-traded, special purpose acquisition corporation (SPAC), will acquire Better Therapeutics in a deal expected to be completed in the summer of this year, with the company continuing to operate as Better Therapeutics […]
Amneal completes acquisition of Kashiv Specialty Pharmaceuticals
Amneal Pharmaceuticals (NYSE:AMRX) announced today that it completed the acquisition of a 98% interest in Kashiv Specialty Pharmaceuticals. Bridgewater, N.J.-based Amneal develops, manufactures and distributes generic and specialty drug products. Kashiv Specialty Pharmaceuticals, a wholly-owned subsidiary of Kashiv BioSiences, develops complex generics, novel drugs and innovative drug delivery platforms, according to a news release. No […]
Intec Pharma, Decoy Biosystems agree to merger
Intec Pharma (NSDQ:NTEC) announced that it entered into a definitive agreement over a merger with Decoy Biosystems. Jerusalem-based Intec Pharma said in a news release that the combined company is slated to grow an immunotherapy platform to battle a variety of tumor types and chronic viral infections with Decoy bringing to the table multi-targeted products […]
Takeda to acquire T-cell engager therapy maker Maverick Therapeutics for $525M
Takeda Pharmaceutical (NYSE:TAK) announced that it is acquiring Maverick Therapeutics in a deal worth up to $525 million. Osaka, Japan-based Takeda exercised its option to acquire Maverick and its T-cell engager Cobra platform and development portfolio, including multiple solid tumor treatments in various clinical stages. Following the closing of the deal, Maverick employees will join […]
PerkinElmer completes Oxford Immunotec acquisition
PerkinElmer (NYSE:PKI) announced today that it completed its previously announced acquisition of Oxford Immunotec. Under the acquisition agreement announced in January, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 million. […]
Amgen to acquire Five Prime Therapeutics for $1.9B
Amgen (NSDQ:AMGN) announced today that it is set to acquire Five Prime Therapeutics (NSDQ:FPRX) for approximately $1.9 billion. Thousand Oaks, Calif.-based Amgen will acquire South San Francisco-based Five Prime for $38 per share in cash, reaching the equity value of approximately $1.9 billion, according to a news release. Amgen is set to add Five Prime’s pipeline […]
Becton Dickinson acquires smart medication device maker GSL Solutions
Becton Dickinson (NYSE:BDX) announced today that it acquired smart medication device developer GSL solutions for an undisclosed amount. Franklin Lakes, N.J.-based BD said in a news release that GSL Solutions develops devices for storing and tracking controlled substances, as well as patient-specific medications that improve the security, efficiency and compliance of medication storage. Additionally, the company […]
Axonics acquires Contura and its Bulkamid bulking agent for $235M
Axonics (NSDQ: AXNX) announced today that it acquired Contura and its flagship Bulkamid product for up to $235 million. London-based Contura’s Bulkamid is a urethral bulking agent for women with stress urinary incontinence (SUI). It is a next-generation hydrogel injected into the urethral wall in a minimally invasive office or outpatient facility procedure to restore the natural closing pressure […]
PerkinElmer to acquire Oxford Immunotec
PerkinElmer (NYSE:PKI) and Oxford Immunotec announced today that they agreed to terms under which the former will acquire the latter. Under the agreement, London-based Oxford Immunotec’s shareholders will be entitled to receive $22 for each outstanding ordinary share, with the terms of the acquisition valuing Oxford Immunotec’s entire issued and to-be-issued ordinary share capital at $591 […]
